ImmunOs Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$11.5M
- Investors
-
21
ImmunOs Therapeutics General Information
Description
Developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases. The company's drugs use proteins that have direct anti-tumour effects that remodel the tumour microenvironment and develop antibodies to block the activation of specific HLA molecules associated with autoimmune diseases, enabling healthcare providers to get biological therapeutics.
Contact Information
Website
www.immunostherapeutics.comCorporate Office
- Wagistrasse 14
- 8952 Schlieren
- Switzerland
Corporate Office
- Wagistrasse 14
- 8952 Schlieren
- Switzerland
ImmunOs Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 05-Aug-2024 | $11.5M | Completed | Clinical Trials - Phase 1 | ||
| 5. Later Stage VC (Series B) | 05-Jun-2022 | Completed | Startup | |||
| 4. Later Stage VC (Series A) | 10-Dec-2019 | Completed | Startup | |||
| 3. Early Stage VC | 08-Dec-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
ImmunOs Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 3,045,001 | $0.011283 | $6.28 | $6.28 | 1x | $6.28 | 10.83% | |
| Ordinary | 98,990 | $0.011283 | $26.2 | $26.2 | 1x | $26.2 | 0.35% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ImmunOs Therapeutics Comparisons
Industry
Financing
Details
ImmunOs Therapeutics Competitors (9)
One of ImmunOs Therapeutics’s 9 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
ImmunOs Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImmunOs Therapeutics Patents
ImmunOs Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4662230-A1 | Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa | Pending | 08-Feb-2023 | ||
| AU-2024217729-A1 | Fusion proteins of ß2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa | Pending | 08-Feb-2023 | ||
| WO-2024165671-A1 | Fusion proteins of ß2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa | Inactive | 08-Feb-2023 | ||
| AU-2022324711-A1 | A modified hla-b57 with increased expression levels | Pending | 05-Aug-2021 | ||
| CA-3227284-A1 | A modified hla-b57 with increased expression levels | Pending | 05-Aug-2021 | A61K38/1774 |
ImmunOs Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ImmunOs Therapeutics Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Double Point Ventures | Venture Capital | Minority | ||
| Fiscus Ventures | Venture Capital | Minority | ||
| Gimv | PE/Buyout | Minority | ||
| Gl Capital | Real Estate | Minority | ||
| Lightspeed Venture Partners | Venture Capital | Minority |
ImmunOs Therapeutics FAQs
-
When was ImmunOs Therapeutics founded?
ImmunOs Therapeutics was founded in 2014.
-
Where is ImmunOs Therapeutics headquartered?
ImmunOs Therapeutics is headquartered in Schlieren, Switzerland.
-
What is the size of ImmunOs Therapeutics?
ImmunOs Therapeutics has 5 total employees.
-
What industry is ImmunOs Therapeutics in?
ImmunOs Therapeutics’s primary industry is Drug Discovery.
-
Is ImmunOs Therapeutics a private or public company?
ImmunOs Therapeutics is a Private company.
-
What is the current valuation of ImmunOs Therapeutics?
The current valuation of ImmunOs Therapeutics is .
-
What is ImmunOs Therapeutics’s current revenue?
The current revenue for ImmunOs Therapeutics is .
-
How much funding has ImmunOs Therapeutics raised over time?
ImmunOs Therapeutics has raised $105M.
-
Who are ImmunOs Therapeutics’s investors?
Double Point Ventures, Fiscus Ventures, Gimv, Gl Capital, and Lightspeed Venture Partners are 5 of 21 investors who have invested in ImmunOs Therapeutics.
-
Who are ImmunOs Therapeutics’s competitors?
NGM Biopharmaceuticals, Immune-Onc Therapeutics, BeOne Medicines, Merck & Co., and Amgen are some of the 9 competitors of ImmunOs Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
